GlassScriptPhysician profile
Markandu Ketheeswaran
NPI 1487608725
$4,182.99
in general payments reported to CMS, 2019-2025
21 companies · $674 in 2025
The $674 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $125 · 2022: $298 · 2023: $2,147 · 2024: $939 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,357 · Education: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,357.19 |
| Education | $402.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $650.68 | 2023-2025 | Rybrevant, Carvykti, Tecvayli |
| Lilly USA, LLC | $477.49 | 2023 | |
| Merck Sharp & Dohme LLC | $419.19 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Seagen INC. | $349.99 | 2022-2023 | Padcev, Tukysa |
| Servier Pharmaceuticals LLC | $263.98 | 2023-2024 | |
| Astellas Pharma US INC | $254.99 | 2024-2025 | Xtandi |
| Genzyme Corporation | $252.62 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $163.51 | 2022-2025 | Opdivo |
| Emd Serono, INC. | $147.71 | 2022-2023 | Bavencio |
| Glaxosmithkline, LLC. | $138.20 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Jazz Pharmaceuticals INC. | $125.71 | 2023 | |
| Genentech USA, INC. | $125.31 | 2020 | |
| Gilead Sciences, INC. | $125.00 | 2024 | Trodelvy |
| Incyte Corporation | $124.99 | 2023 | Monjuvi |
| Pharmaessentia USA Corporation | $124.99 | 2023 | Besremi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $120.00 | 2024 | |
| Pharmacosmos Therapeutics INC. | $100.00 | 2023 | Monoferric |
| Beigene USA, INC. | $100.00 | 2023 | Brukinsa |
| Sumitomo Pharma America, INC. | $80.00 | 2023 | Orgovyx |
| Celgene Corporation | $22.53 | 2025 | Opdivo |
| Foundation Medicine, INC. | $16.10 | 2023 | Foundationone Cdx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Markandu Ketheeswaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.